Pfizer presents positive phase 3 data for abrocitinib in moderate to severe atopic dermatitis
Abrocitinib, an investigational oral Janus kinase 1 (JAK1) inhibitor, met all the co-primary and key secondary endpoints, which were related to skin clearance and itch relief compared to